Ocular Therapeutix (OCUL) Net Cash Flow (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Net Cash Flow of -$68.1 million for Q2 2026, down 264.18% year-over-year from $41.5 million in Q2 2025, and up 3.27% on a QoQ basis from -$70.4 million in Q1 2026.
Ocular Therapeutix (OCUL) Net Cash Flow (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Net Cash Flow for 14 years, with the latest figure at -$68.1 million in Q2 2026.
- Net Cash Flow for Q2 2026 came in at -$68.1 million, down 264.18% year-over-year; the trailing twelve-month figure through Jun 2026 was $207.5 million (up 402.68% YoY), and the FY2025 annual result was $345.0 million, up 75.87% from the prior year.
- Net Cash Flow advanced to -$68.1 million in Q2 2026, from -$70.4 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $392.3 million in Q4 2025 and troughed at -$70.4 million in Q1 2026.
- A 5-year average of $24.1 million and a median of -$18.7 million in 2022 frame the typical range for Net Cash Flow.
- The widest annual swing landed in 2024, when Net Cash Flow jumped 1333.48%; it then plunged 264.18% in 2026.
- A 5-year view of Net Cash Flow shows it stood at -$18.6 million in 2022, then surged by 557.14% to $85.3 million in 2023, then sank by 141.19% to -$35.1 million in 2024, then jumped by 1217.06% to $392.3 million in 2025, then tumbled by 117.35% to -$68.1 million in 2026.
- Per Business Quant data, the three most recent Net Cash Flow figures were -$68.1 million in Q2 2026, -$70.4 million in Q1 2026, and $392.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | -68.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -68.06 Mn |
| Jun 30, 2026 | -68.06 Mn |
| Mar 31, 2026 | -70.36 Mn |
| Mar 31, 2026 | -70.36 Mn |
| Dec 31, 2025 | 392.29 Mn |
| Dec 31, 2025 | 392.29 Mn |
| Sep 30, 2025 | -46.36 Mn |
| Sep 30, 2025 | -46.36 Mn |
| Jun 30, 2025 | 41.45 Mn |
| Jun 30, 2025 | 41.45 Mn |
| Mar 31, 2025 | -42.42 Mn |
| Mar 31, 2025 | -42.42 Mn |
| Dec 31, 2024 | -35.12 Mn |
| Dec 31, 2024 | -35.12 Mn |
| Sep 30, 2024 | -32.47 Mn |
| Sep 30, 2024 | -32.47 Mn |
| Jun 30, 2024 | -23.35 Mn |
| Jun 30, 2024 | -23.35 Mn |
| Mar 31, 2024 | 287.08 Mn |
| Mar 31, 2024 | 287.08 Mn |